Recently, TowardPi Medical, a leading company in high-end ophthalmic medical equipment in China, completed 200 million yuan in Series D financing. This round of financing was led by Matrix Partners China, with participation from other institutions including GTJA Investment Group, etc.

Founded in 2017, TowardPi Medical's core technology originates from the transformation of scientific and technological achievements of Tsinghua University. The core technical team consists of dozens of Tsinghua teachers, students, and alumni. Since its establishment, the company has achieved breakthroughs in various categories of high-end ophthalmic equipment through the vertical integration of clinical needs, innovative system functions, and high-performance upstream components.

Currently, TowardPi Medical has established four major product lines: OCT, surgical microscopes, ultra-widefield cameras, and biometers. Significant progress has also been made in its research projects, such as phacovitrectomy and femtosecond lasers.

Key milestones include:

• November 2020: TowardPi launched its first major product, the "BMizar" ophthalmic OCT, at the national ophthalmology conference in Xiamen (CCOS2020). This product achieved the world's fastest scanning speed of 400,000 scans per second and pioneered rapid ultra-widefield OCTA blood flow imaging, which was subsequently included in the Chinese diabetic retinopathy diagnostic guidelines.

• March 2021: TowardPi released the "Zalioth" optical biometer, featuring "panoramic dynamic axial length imaging," marking a new era in biometric technology.

• December 2022: At the national retinal disease conference in Changsha (Retina China 2022), TowardPi unveiled the "Focean" intraoperative OCT navigation surgical microscope prototype, signifying its entry into the high-end market of this crucial ophthalmic equipment segment.

• September 2023: At the national ophthalmology conference in Changsha (CCOS2023), TowardPi introduced the "Baryon" digital holographic intraoperative OCT navigation surgical microscope prototype, completing its strategic layout in the high-end surgical microscope market.

• April 2024: TowardPi held a launch event for the "Zursa" ultra-widefield fundus camera, further enhancing its presence in the high-end ophthalmic examination equipment sector.

• June 2024: At the national retinal disease conference in Wuxi (Retina China 2024), TowardPi launched its high-end surgical microscopes, "Baryon" and "Focean." The event included standard wet-lab sessions where renowned ophthalmologists performed animal eye surgeries, experiencing the "sci-fi level" digital holographic intraoperative navigation. The products received unanimous praise, highlighting the breakthrough in domestically developed high-end ophthalmic surgical microscopes.

Since its establishment, TowardPi Medical has leveraged the domestic optoelectronics industry and research institution resources, focusing on the independent development of key optoelectronic components. Even when product system functions were limited by commercially available components, the company achieved performance breakthroughs through foundational technology in a vertical direction. This mode has also driven technological advancements in the medical direction of the domestic optoelectronic components field, demonstrating the direct driving effect of new quality productivity on medical equipment companies.

According to the "Blue Book on the Current Situation and Future Development Trends of the High-end Ophthalmic Equipment Industry" released by Frost & Sullivan, in 2023, TowardPi Medical's ophthalmic OCT products achieved a market share of 27% in public hospitals, ranking first in the Chinese market. TowardPi is also the first Chinese company to achieve a "full product line" layout of high-end ophthalmic medical equipment.

Encouragingly, the trust of Chinese ophthalmologists in domestic products has significantly increased thanks to outstanding domestic companies like TowardPi Medical. It is believed that with the launch of TowardPi’s high-end surgical microscopes, "Baryon" and "Focean," and the promotion of new products such as "Zursa" and "Zalioth," the comprehensive localization of ophthalmic medical equipment will be rapidly realized.

Additionally, TowardPi Medical's products have also been installed internationally, including Italy, Switzerland, France, Netherlands, Greece, Singapore, Mexico, Columbia, etc.. Its global network is gradually growing, and its overseas revenue is expected to be growing rapidly after regional regulation clearance.

Currently, late-stage project financing in the primary market has generally slowed down, but TowardPi Medical's recent investment from top-tier institutions fully reflects its outstanding technical strength and excellent market performance.

For such a high-growth industry-leading company—

David Xu, Founding Managing Partner of Matrix Partners China, stated: "China has the largest number of patients with common ophthalmic diseases. With the popularization of electronic products and an aging population, the clinical demand in the ophthalmic field continues to rise, driving the rapid development of the ophthalmic precision diagnosis and treatment market. Since its establishment, TowardPi Medical has broken the import monopoly through independent innovation at the foundational level within just a few years and is now leading in multiple product lines domestically, with some breakthroughs overseas. We look forward to the company becoming a globally competitive platform for high-end ophthalmic diagnostic and treatment equipment."

Yu Jianlin, Deputy General Manager of GTJA Investment Group, stated: "We are very pleased to participate in this round of financing for TowardPi Medical. We firmly believe in TowardPi’s leading advantage and comprehensive strength in the ophthalmic equipment track. The ophthalmic medical equipment market is a hundred-billion-level track, long monopolized by imports, with significant space for domestic substitution. As a leading company in the ophthalmic medical equipment track, TowardPi has launched the world's fastest 400,000 scans per second OCT in ophthalmic OCT, truly achieving globally leading product performance. Its OCT market share has surpassed imports, becoming the leader in the country. TowardPi has the strongest R&D team in the industry, having laid out four major diagnostic products: OCT, ophthalmic surgical microscopes, ultra-widefield fundus cameras, and optical biometers. The product performance fully benchmarks and even surpasses some imported products, continuously delivering R&D milestones. As a professional investment institution focused on the healthcare industry, GTJA Investment Group will firmly support the development of TowardPi Medical. We look forward to TowardPi’s entire product line benefiting ophthalmic patients worldwide, meeting unmet clinical needs globally, and becoming a globally renowned brand in the ophthalmic equipment field."